Print   



        

Northwest Biotherapeutics, Inc.

('NWBT', 'Northwest' or the 'Company')

            

Northwest Secures US$700,000 Equity Financing

Bethesda, MD- February 10, 2009 - Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC BB: NWBO) announces today receipt of US$700,000 in cash from Al Rajhi Holdings through the subscription of 1,000,000 new shares in the form of the Company's common stock at US$0.70 per share. The new stock is expected to be admitted to trading on AIM on 16 February 2009. The shares will not be tradable on the Company's OTC bulletin board listing in the US without prior registration. 

The proceeds will be used to support the Company's ongoing working capital needs. The Company's directors consider, having consulted with its Nominated Advisor, Collins Stewart Europe Limited, that the terms of this financing are fair and reasonable in so far as all of its shareholders are concerned.

'We are very pleased to have completed another interim financing despite severely adverse general market conditions,' said NWBT's Chief Executive Officer Alton Boynton. 'We look forward to continuing the financing discussions currently under way with several additional parties for short-term and long-term funding of the Company'.

The US$700,000 received by the Company will be sufficient to fund its cash needs during February.  The Company remains in an advanced stage of negotiations with several different providers for additional near-term funding and longer term funding, which it hopes to complete during H1 of 2009. 

The Company will need to raise additional capital to fund its clinical trials and other operating activities and to repay indebtedness in due course. Shareholders should be aware that if the Company's capital raising efforts are unsuccessful, this will have a material adverse effect on the Company's financial position and operations. 

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'expects,' 'believes,' 'intends,' and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated. Additional information on these and other factors, which could affect the company's results, is included in its Securities and Exchange Commission ('SEC') filings. Finally, there may be other factors not mentioned above or included in the company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

For further information, please contact:

Northwest Biotherapeutics, Inc.
Alton L. Boynton, Chief Executive Officer	+1 240 497 9024
Buchanan Communications
Lisa Baderoon (lisab@buchanan.uk.com) / Mary-Jane Johnson / Catherine Breen	+44 (0)20 7466 5000
Collins Stewart Europe Limited
Adrian Hadden/ Adam Cowen	+44 (0)20 7523 8350

ENDMSCTLMTTMMIMTML